Xaliproden

Xaliproden
Nome IUPAC
	1-(2-naftalen-2-iletil)-4-[3-(trifluorometil)fenil]-3,6-diidro-2H-piridina
Caratteristiche generali
Formula bruta o molecolare	C24H22F3N
Massa molecolare (u)	381.43339
Numero CAS	135354-02-8
Codice ATC	N07XX03
PubChem	128919
DrugBank	DBDB06393
SMILES	C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3
Indicazioni di sicurezza
	Modifica dati su Wikidata · Manuale

Xaliproden (nome in codice SR57746) è un farmaco che agisce come un 5HT 1A agonista. Ha effetti in vitro neuroprotettivi e neurotrofici, ed è stato proposto per l'uso nel trattamento di diverse malattie neurodegenerative compresa sclerosi laterale amiotrofica (ALS) e la malattia di Alzheimer.

Lo sviluppo di xaliproden, in queste due indicazioni, è stato interrotto nel 2007, a seguito dell'analisi dei dati di fase III; mentre continua ad essere studiato per il trattamento della neuropatia periferica indotta dalla chemioterapia.

Note

↑ A Appert-Collin, FH Duong, P Passilly Degrace, JM Warter, P Poindron e JP Gies, MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden, in International journal of immunopathology and pharmacology, vol. 18, n. 1, 2005, pp. 21-31, PMID 15698508.
↑ C Labie, C Lafon, C Marmouget, P Saubusse, J Fournier, PE Keane, G Le Fur e P Soubrié, Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex, in British Journal of Pharmacology, vol. 127, n. 1, 1999, pp. 139-44, DOI:10.1038/sj.bjp.0702545, PMC 1566010, PMID 10369466.
↑ FH Duong, JM Warter, P Poindron e P Passilly, Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons, in British Journal of Pharmacology, vol. 128, n. 7, 1999, pp. 1385-92, DOI:10.1038/sj.bjp.0702910, PMC 1571767, PMID 10602316.
↑ V Meininger, G Bensimon, WR Bradley, B Brooks, P Douillet, AA Eisen, L Lacomblez, PN Leigh e W Robberecht, Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials, in Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, vol. 5, n. 2, 2004, pp. 107-17, DOI:10.1080/14660820410019602, PMID 15204012.
↑ Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P., Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats, in Invest Radiol, vol. 37, n. 6, 2002, pp. 321-7, DOI:10.1097/00004424-200206000-00003, PMID 12021588.
↑ E Susman, Xaliproden lessens oxaliplatin-mediated neuropathy, in The lancet oncology, vol. 7, n. 4, 2006, p. 288, DOI:10.1016/S1470-2045(06)70639-8, PMID 16598880.
↑ S Wolf, D Barton, L Kottschade, A Grothey e C Loprinzi, Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies, in European journal of cancer (Oxford, England : 1990), vol. 44, n. 11, 2008, pp. 1507-15, DOI:10.1016/j.ejca.2008.04.018, PMID 18571399.

Portale Chimica: il portale della scienza della composizione, delle proprietà e delle trasformazioni della materia

[1] A Appert-Collin, FH Duong, P Passilly Degrace, JM Warter, P Poindron e JP Gies, MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden, in International journal of immunopathology and pharmacology, vol. 18, n. 1, 2005, pp. 21-31, PMID 15698508.

[2] C Labie, C Lafon, C Marmouget, P Saubusse, J Fournier, PE Keane, G Le Fur e P Soubrié, Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex, in British Journal of Pharmacology, vol. 127, n. 1, 1999, pp. 139-44, DOI:10.1038/sj.bjp.0702545, PMC 1566010, PMID 10369466.

[3] FH Duong, JM Warter, P Poindron e P Passilly, Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons, in British Journal of Pharmacology, vol. 128, n. 7, 1999, pp. 1385-92, DOI:10.1038/sj.bjp.0702910, PMC 1571767, PMID 10602316.

[4] V Meininger, G Bensimon, WR Bradley, B Brooks, P Douillet, AA Eisen, L Lacomblez, PN Leigh e W Robberecht, Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials, in Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, vol. 5, n. 2, 2004, pp. 107-17, DOI:10.1080/14660820410019602, PMID 15204012.

[5] Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P., Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats, in Invest Radiol, vol. 37, n. 6, 2002, pp. 321-7, DOI:10.1097/00004424-200206000-00003, PMID 12021588.

[6] E Susman, Xaliproden lessens oxaliplatin-mediated neuropathy, in The lancet oncology, vol. 7, n. 4, 2006, p. 288, DOI:10.1016/S1470-2045(06)70639-8, PMID 16598880.

[7] S Wolf, D Barton, L Kottschade, A Grothey e C Loprinzi, Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies, in European journal of cancer (Oxford, England : 1990), vol. 44, n. 11, 2008, pp. 1507-15, DOI:10.1016/j.ejca.2008.04.018, PMID 18571399.